在接受塞马格卢提德的成年人中,Helicobacter pylori根除的改善:基于人口的倾向性得分调整的分析
Asaf Ness1,2, Zohar Levi2,3, Rachel Gingold Belfer2,3
1Internal Medicine E, Rabin Medical Center, Petah Tikva, Israel.
Helicobacter
|February 4, 2025
概括
类似葡萄糖类-1 (GLP-1) 受体激动剂,如塞马格卢提德,当与抗生素一起使用时,可能会改善Helicobacter pylori (H. pylori) 根除率. 这一发现表明,接受H. pylori治疗的患者可能会受益.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 传染性疾病 传染性疾病
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激活剂用于糖尿病和肥胖症,影响胃排空.
- 成功治疗Helicobacter pylori (H. pylori) 需要精确的抗生素剂量.
- GLP-1药物对H.pylori根除的影响尚不清楚.
研究的目的:
- 研究GLP-1受体激活剂对抗生素治疗H.pylori感染的成功的影响.
- 为了确定GLP-1药物使用是否会影响糖尿病和/或肥胖患者的H. pylori根除率.
主要方法:
- 在2014-2023年期间接受治疗的成年H. pylori患者的回顾性分析.
- 患者按糖尿病,肥胖和GLP-1药物暴露分组.
- 使用1:2倾向度得分匹配的数据集来评估根除成功.
主要成果:
- 与非使用者 (p=0.007) 相比,塞马格卢提德的使用与明显更高的H. pylori根除率 (93.8%) 相关.
- 倾向性评分分析证实了塞马格卢提德与消除增加的显著关联 (OR 2.89,p=0.014).
- 杜拉古类和利拉古类对根除率没有显著影响.
结论:
- 与H.pylori感染的抗生素同时服用塞马格卢提德增加了成功根除的可能性.
- 塞马格卢提德可以提高H. pylori治疗结果,特别是在糖尿病和肥胖患者中.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
320
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
320
01:26Peptic Ulcer Disease IV: Management
60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
80
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
80
01:23Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
01:23Gastritis III: Clinical Manifestations and Management
129
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
129
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118